



RECEIVED
ATTENTION: BOX AFTER FINAL
AMENDMENT AND REPLY AFTER FINAL REJECTION UNDER 37 C.F.R. § 1.116
EXAMINING GROUP 1616
SEP 10 2002

TECH CENTER 1600/2000 Application No. 09/530,375
Attorney Docket No. 1142.0236-00
Customer No. 22,852

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Anthony ORMEROD et al.) Group Art Unit: 1616
Application No.: 09/530,375) Examiner: M. Williamson
Filed: July 7, 2000)
For: SKIN PENETRATION)
ENHANCING COMPONENTS)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

AMENDMENT AND REPLY UNDER 37 C.F.R. § 1.116

In reply to the Office Action dated March 12, 2002, Applicants respectfully request reconsideration of this application in light of the following amendment and remarks. The period for response has been extended three months to September 12, 2002, by the accompanying petition and fee.

IN THE CLAIMS:

Please cancel claim 26 and amend claim 24 as follows:

24. (Twice Amended) A topical formulation for the treatment of a dermatological condition which comprises a macrocyclic lactone antibiotic chosen from azithromycin or clarithromycin or an immunosuppressive macrolide chosen from sirolimus, FK506 or SDZ ASM 981, and a permeation modulator which are present in

↳ aScomycin

FINNEGAN
HENDEBORN
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com